Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
09/2005
09/15/2005US20050203180 fewer side-effects by showing no hormone properties; enhancing the learning and memory-retention, treat dementia
09/15/2005US20050203173 PI-3 kinase inhibitor prodrugs
09/15/2005US20050203158 Substituted benzimidazole compounds
09/15/2005US20050203154 Novel tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
09/15/2005US20050203135 Modulating adhesion between intracellular adhesion molecules (e.g. ICAM-1, -2 and -3) and the leukocyte integrin family of receptors; inflammatory disorders, allergies, and autoimmune diseases such as psoriasis, rheumatoid arthritis, asthma, multiple sclerosis, transplant rejection
09/15/2005US20050203127 2-(Phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses
09/15/2005US20050203126 Inhibitors of basic fibroblast growth factors (FGFs); treating cancer, rheumatoid arthritis, inflammatory bowel disease, cardiovascular disorders, diabetic retinopathy, achondroplasia, hypochondoplasia, or thanathophoric dysplasia
09/15/2005US20050203125 Treating pseudobulbar affect or emotional lability; nervous system, brain, and neurodegenerative disorders; analgesics; neuropathic pain; dextromethorphan hydrobromide and quinidine sulfate
09/15/2005US20050203114 Pyrimidine-indole derivatives; cancer, autoimmunological, metabolic, inflammatory, infection (bacterial, viral, yeast, fungal, etc.), diseases of the central nervous system, degenerative neural disease, allergy/asthma, dermatology, angiogenesis, neovascularization, vasculogenesis, and cardiovascular
09/15/2005US20050203112 Bicyclic amides
09/15/2005US20050203109 Novel Compounds
09/15/2005US20050203107 Reversible inhibitors of cysteine proteases S, K, F, L and B; inhibiting Cathepsin S; analgesics; 1-[9-(4-Chlorophenyl)-2-cyano-9H-purin-6-yl]-L-prolinamide for example
09/15/2005US20050203103 Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
09/15/2005US20050203100 Administering acridin-9-yl-[4-(4-methylpiperazin-1-yl)-phenyl]amine (JP-1302); cognition activators, drug abuse, alcoholism, cigarette smoking cessation, schizophrenia, Tourette*s syndrome, epilepsy, psychosis; sexual, psychological, obsessive-compulsive, or nervous system disorders; psychiatry
09/15/2005US20050203098 Use of tyrosine kinase inhibitors for treating substance use disorders
09/15/2005US20050203096 Compounds to treat Alzheimer's disease
09/15/2005US20050203093 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
09/15/2005US20050203080 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
09/15/2005US20050203079 Serotonin (5-HT) 2c receptors; antidepressants, anxiolytic agents; 3-(3,4-Dichloro-phenyl)-3-hydroxy-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one for example
09/15/2005US20050203068 Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same
09/15/2005US20050203066 Preventing mitochondrial respiratory chain dysfunction in mammal by administering a pyrimidine nucleotide precursor and pyruvic acid, ester or salt; neurodegenerative, muscular, urogenital, or developmental disorders; autism, neuropathic pain, headaches; anticarcinogenic agents; cognition activators
09/15/2005US20050203055 Administering an effective amount of a sulfated polysaccharide for therapy and prophylaxis of fungal infection
09/15/2005US20050203016 Method of drug delivery through selective targeting, of biological tissues containing populations of receptor proteins, with novel conjugate molecules
09/15/2005US20050203003 Contulakin-G, analogs thereof and uses therefor
09/15/2005US20050202474 Phosphodiesterases
09/15/2005US20050202412 Potentiators of serotonin reuptake inhibitors; cyclohexane carboxylic acid-((1r)-1-cyclohexylmethyl-2-(4-(2-methoxy phenyl)-piperazin-1-yl)ethyl)amide derivatives; for treatment of schizophrenia, paranoia and mano-depressive illness
09/15/2005US20050202148 Preparation of microbial oil
09/15/2005US20050202111 Extract of Mucuna pruriens cotyledon powder, defatted with aqueous ethanol
09/15/2005US20050202091 Stable pharmaceutical composition comprising erythropoietin
09/15/2005US20050202032 Use of neglected target tissue antigens in modulation of immune responses
09/15/2005US20050202008 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
09/15/2005US20050201986 Cell targeting compositions and methods of using the same
09/15/2005US20050201980 Method for short-term and long-term drug dosimetry
09/15/2005CA2558376A1 Method and device for releasing flavor and odor substances
09/15/2005CA2558278A1 Diaryl-substituted five-membered heterocycle derivative
09/15/2005CA2558274A1 Cycloalkanopyridine derivative
09/15/2005CA2558198A1 Crystalline composition containing escitalopram oxalate
09/15/2005CA2558109A1 Heteroaryl-fused pyrazolo derivatives
09/15/2005CA2557766A1 Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
09/15/2005CA2557758A1 Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder
09/15/2005CA2557268A1 Indazole derivatives and pharmaceutical compositions containing them
09/15/2005CA2556969A1 Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
09/15/2005CA2556771A1 Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
09/15/2005CA2556383A1 Use of n-piperidine derivatives for the treatment of neurodegenerative pathologies
09/15/2005CA2556380A1 Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
09/14/2005EP1574578A1 Monomeric protein of the TGF-beta family
09/14/2005EP1574506A1 Remedies
09/14/2005EP1574500A1 Quinoline derivative as diagnostic probe for disease with tau protein accumulation
09/14/2005EP1574219A2 Method of inhibiting fibrosis with a somatostatin agonist
09/14/2005EP1574207A1 Cosmetic use of viscous compositions containing carbon dioxide
09/14/2005EP1573450A2 System and method for transparent early detection, warning, and intervention during a medical procedure
09/14/2005EP1573039A2 Compositions and methods for diagnosing and treating mood disorders
09/14/2005EP1572995A2 Novel proteins and nucleic acids encoding same
09/14/2005EP1572898A2 Novel proteins and nucleic acids encoding same
09/14/2005EP1572892A2 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
09/14/2005EP1572887A2 Neural regeneration peptide and methods for their use in treatment of brain damage
09/14/2005EP1572877A2 Drug metabolizing enzymes
09/14/2005EP1572876A2 Transcriptional regulation of target genes
09/14/2005EP1572875A2 Receptors and membrane-associated proteins
09/14/2005EP1572874A2 Antibodies that immunospecifically bind to trail receptors
09/14/2005EP1572871A2 T1r3 a novel taste receptor
09/14/2005EP1572863A2 Method for identifying inhibitors of g protein coupled receptor signaling
09/14/2005EP1572725A1 Novel chi-conotoxin peptides (-i)
09/14/2005EP1572700A1 Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof
09/14/2005EP1572698A1 3-substituted 3,4-dihydro-thieno[2,3-d]pyrimidine-4-one-derivatives, production and use thereof
09/14/2005EP1572685A1 Substituted benzodioxepins
09/14/2005EP1572679A2 Crfr1 selective ligands
09/14/2005EP1572666A1 3h-quinazolin-4-one derivatives
09/14/2005EP1572659A2 The use of 4-phenyl substituted tetrahydroisoquinolines in the treatment of pain, migraine and urinary incontinence
09/14/2005EP1572658A1 The use of 4-phenyl-substituted tetrahydroisoquinolines in the treatment of pain, migraine headaches and urinary incontinence
09/14/2005EP1572655A2 Novel arylheteroalkylamine derivatives
09/14/2005EP1572653A1 Saturated and unsaturated heteroarylcycloalkylmethyl amines as anti-depressants
09/14/2005EP1572635A1 Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
09/14/2005EP1572300A1 Combination for the treatment of adhd
09/14/2005EP1572215A1 Benzo[d]azepine derivatives for the treatment of neurological disorders
09/14/2005EP1572211A1 Therapeutic applications of 2-substituted 4-heteroarylpyrimidines
09/14/2005EP1572205A2 Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
09/14/2005EP1572204A1 Synergistic compositions with analgesic properties comprising n-acylated 4-hydroxyphenylamine derivatives
09/14/2005EP1572200A1 Aminoindazole derivatives and use thereof as kinase inhibitors
09/14/2005EP1572188A1 Pregabalin derivatives for the treatment of fibromyalgia and other disorders
09/14/2005EP1572187A1 Pregabalin and derivatives thereof for the treatment of fibromyalgia and other related disorders
09/14/2005EP1572184A1 Gabapentin analogues for fibromyalgia and other related disorders
09/14/2005EP1572183A1 Alpha-2-delta ligand for the treatment of sexual dysfunction
09/14/2005EP1572179A1 Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox1/2 inhibitor
09/14/2005EP1572174A1 Prevention and treatment of alzheimer's disease
09/14/2005EP1572172A1 Alpha2delta ligands for different pharmaceutical uses
09/14/2005EP1572167A1 Transdermal buprenorphine dosage regimen for analgesia
09/14/2005EP1572158A1 A new oral immediated release dosage form
09/14/2005EP1572129A2 Amidine derivatives for treating amyloidosis
09/14/2005EP1572112A2 3-(pyridinyl-piperazin-1-yl)-phenylethyl amides as potassium channel openers
09/14/2005EP1572076A2 Helical peptidomimetics
09/14/2005EP1572074A2 Stabilized synthetic immunogen delivery system
09/14/2005EP1572071A2 Systems and methods for treating patients with processed lipoaspirate cells
09/14/2005EP1572068A2 Arylheteroalkalylamine derivatives and their use as inhibitors of nitric oxide synthase
09/14/2005EP1572066A2 Novel method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within mmp-2
09/14/2005EP1572064A2 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration
09/14/2005EP1529048A4 Methods for the synthesis of substituted purines
09/14/2005EP1461318B1 Tetrahydroquinoline analogues as muscarinic agonists
09/14/2005EP1404682B1 Method of inhibiting ptp 1b and/or t-cell ptp and/or other ptpases with an asp residue at position 48
09/14/2005EP1401432B1 Imidazole derivatives for modulating sodium channels
1 ... 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 ... 1833